Bourgeon Capital Management LLC continued to hold its stake in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 34,500 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bourgeon Capital Management LLC’s holdings in Achillion Pharmaceuticals were worth $158,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Norges Bank purchased a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $4,623,000. Highbridge Capital Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at about $149,000. Wells Fargo & Company MN increased its stake in shares of Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 22,931 shares during the period. Emory University increased its stake in shares of Achillion Pharmaceuticals by 7.1% in the first quarter. Emory University now owns 486,438 shares of the biopharmaceutical company’s stock valued at $2,048,000 after buying an additional 32,336 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Achillion Pharmaceuticals by 12,296.5% in the first quarter. Bank of Montreal Can now owns 53,305 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 52,875 shares during the period. Institutional investors and hedge funds own 70.83% of the company’s stock.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 4.695 on Friday. Achillion Pharmaceuticals, Inc. has a 12 month low of $3.15 and a 12 month high of $9.49. The firm’s market capitalization is $642.09 million. The firm’s 50-day moving average is $4.39 and its 200 day moving average is $4.13.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). During the same quarter in the previous year, the firm earned ($0.14) earnings per share. On average, equities research analysts anticipate that Achillion Pharmaceuticals, Inc. will post ($0.63) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://theolympiareport.com/2017/08/12/achillion-pharmaceuticals-inc-achn-position-held-by-bourgeon-capital-management-llc.html.

Several equities research analysts recently issued reports on ACHN shares. BidaskClub downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Robert W. Baird raised their target price on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, April 24th. Leerink Swann upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $4.00 to $6.00 in a research note on Thursday, May 18th. Finally, Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $8.25.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.